Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
Journal of Virology|December 30, 2016
An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus EntryKathleen McCaffrey, Irene Boo, Catherine M Owczarek, et al.Hepatology (Baltimore, Md.)|March 30, 2007
A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virusJoseph Torresi, Owen M Stock, Alexandra E Fischer, et al.Viral Immunology|March 1, 2018
Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 AgonistsDale Christiansen, Linda Earnest-Silveira, Brendon Chua, et al.Journal of Virology|February 23, 2018
Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization EpitopesJun Gu, Joshua Hardy, Irene Boo, et al.Journal of Virology|September 18, 2015
Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable RegionYousef Alhammad, Jun Gu, Irene Boo, et al.Journal of Virology|January 5, 2022
Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea PigsJoey McGregor, Joshua M Hardy, Chan-Sien Lay, et al.European Journal of Immunology|December 18, 2025
Functional Antigen-Specific CD8 TSCM Responses Are Associated with Repeated Clearance of Hepatitis C Virus InfectionYanran Zhao, Elizabeth Keoshkerian, Hui Li, et al.The Journal of General Virology|May 26, 2016
Calsyntenin-1 mediates hepatitis C virus replicationZunaira Awan, Enoch S E Tay, Nicholas S Eyre, et al.Hepatology (Baltimore, Md.)|December 21, 2016
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigsPatricia T Vietheer, Irene Boo, Jun Gu, et al.Clinical & Translational Immunology|July 26, 2024
Serological responses and clinical outcomes following a three-dose primary COVID-19 vaccine schedule in kidney transplant recipients and people on dialysisDhakshayini Tharmaraj, Irene Boo, Jessie O'Hara, et al.Pageof 3